Acute Appendicitis in Patients with End-Stage Renal Disease

Chao, Pei Wen; Ou, Shuo Ming; Chen, Yung Tai; Lee, Yi Jung; Wang, Feng Ming; Liu, Chia Jen; Wu, Yang Chang; Chen, Tzeng Ji; Chen, Tzen Wen; Li, Szu Yuan

doi:10.1007/s11605-012-1961-z

Cited by 11 publications

(8 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The index date was defined as the date of the first anticoagulant prescription observed on or after June 1, 2012, the date that rivaroxaban treatment began to be reimbursed in the NHI program. Chronic dialysis was defined as 1) having at least two separate outpatient procedure codes indicating dialysis treatment was undergone for more than 90 days, or 2) being enrolled in the “registry for patients with catastrophic illness” of the NHI program because of chronic renal dialysis 19 , 20 .…”

Section: Methodsmentioning

confidence: 99%

Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study

Huang

Lin

Cheng

et al. 2018

Sci Rep

View full text Add to dashboard Cite

The objective of this study is to evaluate the effectiveness of different rivaroxaban dosage regimens in preventing ischemic stroke and systemic thromboembolism among Asians. A retrospective cohort study was conducted on data from nationwide insurance claims in Taiwan. Patients with non-valvular atrial fibrillation under warfarin or rivaroxaban therapy were included. Propensity score matching was used to balance the covariates, and Cox-proportional hazard models were applied to compare the effectiveness and safety of each treatment group. Rivaroxaban was associated with a significantly lower risk of venous thromboembolism (hazard ratio [HR]: 0.51; 95% confidence interval [CI]: 0.29–0.92, P = 0.02) and intracranial hemorrhage (HR: 0.48; 95% CI: 0.32–0.72, P < 0.001) than warfarin. Rivaroxaban 20 mg and 15 mg were associated with a significantly lower risk of ischemic stroke (20 mg, HR: 0.48; CI: 0.29–0.80, P = 0.005; 15 mg, HR: 0.69; CI: 0.53–0.90, P = 0.005), but rivaroxaban 10 mg was not. In the subgroup analysis of patients older than 65 years, the results were generally the same, except that rivaroxaban had a significantly lower risk of ischemic stroke than warfarin.

show abstract

Section: Methodsmentioning

confidence: 99%

Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study

Huang

Lin

Cheng

et al. 2018

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The endpoint of the study was the occurrence of any of the following: gastroesophageal reflux (GERD; ICD-9-CM code 530.11 and 530.81), 17 peptic ulcer disease (PUD; 531, 532, and 533), 16 mesenteric ischemia (557), 13 intestinal obstruction or adhesions (560, 568.0, 614.6), appendicitis (540–541), 12 lower GI diverticula or bleeding (562.02, 562.03, 562.1, 569.3, 569.83, 569.85, 569.86, 578.1), 28 liver cirrhosis (571.2, 571.5, 571.6), 29 acute pancreatitis (577.0), 30 or abdominal hernia (550–553). 18 …”

Section: Methodsmentioning

confidence: 99%

Different Risk of Common Gastrointestinal Disease Between Groups Undergoing Hemodialysis or Peritoneal Dialysis or With Non-End Stage Renal Disease

et al. 2015

View full text Add to dashboard Cite

show abstract

“…For the verification of ESRD on chronic dialysis, after careful exclusion of the causes of acute renal failure, supported medical records, examination reports, and imaging studies with a comprehensive review by nephrology specialists are required. 37 For cancer verification, pathologic evidence is required and laboratory and imaging studies also must be peer reviewed. 38…”

Section: Materials and Methods Data Sourcementioning

confidence: 99%

Nonsteroidal anti-inflammatory drug use is associated with cancer risk reduction in chronic dialysis patients

Chen

Chao

et al. 2013

Kidney International

Self Cite

View full text Add to dashboard Cite

Previous studies have shown that nonsteroidal anti-inflammatory drug (NSAID) use might be associated with a lower risk of developing cancer in the general population. Patients on dialysis have increased risk for cancer, but there are no studies to determine the relationship between NSAID use and cancer risk in these patients. To identify any association between NSAID use and cancer risk in patients with end-stage renal disease on dialysis, we used Taiwan's National Health Insurance database to conduct a nationwide population-based, propensity score-matched cohort study. All cancers between groups were compared by Cox proportional hazards models. Compared to nonuse of NSAIDs, the use of non-COX-2-selective inhibitors (hazard ratio 0.81, 95% confidence interval 0.67-0.97) or COX-2-selective inhibitors (0.78, 0.62-0.98) was associated with a lower risk of developing cancer. NSAID use reduced the risk of respiratory (0.39, 0.19-0.79), breast (0.41, 0.19-0.89), kidney (0.58, 0.38-0.88), digestive tract (0.64, 0.49-0.85), and bladder cancers (0.73, 0.55-0.96). NSAID use, however, significantly increased risk for upper gastrointestinal bleeding (odds ratio, 1.15, 1.07-1.23) but not adverse cardiac or cerebrovascular events. Thus, NSAID use was associated with a lower risk of developing cancer in chronic dialysis patients; however, they should still be used with caution due to the side effects of gastrointestinal bleeding.

show abstract

Acute Appendicitis in Patients with End-Stage Renal Disease

Cited by 11 publications

References 37 publications

Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study

Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study

Different Risk of Common Gastrointestinal Disease Between Groups Undergoing Hemodialysis or Peritoneal Dialysis or With Non-End Stage Renal Disease

Nonsteroidal anti-inflammatory drug use is associated with cancer risk reduction in chronic dialysis patients

Contact Info

Product

Resources

About